Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CFNKG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ZW-220
|
|||||
| Synonyms |
ZW 220; ZW220
Click to Show/Hide
|
|||||
| Organization |
Zymeworks BC, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 2 Indication(s)
Non-small cell lung cancer [ICD11:2C25]
Clinical candidate
Ovarian cancer [ICD11:2C73]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Fully humanized Anti-SLC34A2 IgG1 mAb
|
Antibody Info | ||||
| Antigen Name |
Sodium-dependent phosphate transport protein 2B (SLC34A2)
|
Antigen Info | ||||
| Payload Name |
ZD06519
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly-AM
|
Linker Info | ||||
| Conjugate Type |
Endogenous interchain cysteines.
|
|||||
| Combination Type |
MC-GGFG-AM-ZD06519
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.